Genistein (soy isoflavone) / Smo Cancer Research Results

GEN, Genistein (soy isoflavone): Click to Expand ⟱

Features: Estrogen-like activity

Genistein is a naturally occurring isoflavone predominantly found in soy products.
It binds estrogen receptors (with relative preference for ERβ over ERα), inhibits certain tyrosine kinases, and modulates PI3K/AKT, NF-κB, MAPK, and cell-cycle pathways in preclinical cancer models. It is also reported to influence angiogenesis and epigenetic regulation. Oral exposure produces conjugated metabolites (glucuronides/sulfates), and free genistein plasma levels are typically much lower than many in-vitro µM concentrations.
-soy isoflavone
Anticancer effects through several mechanisms:
-Modulation of Hormone Activity: can bind to estrogen receptors(hormone-dependent cancers like breast and prostate cancer).
-Inhibition of Cell Proliferation:- -inducing cell cycle arrest.
-Induction of Apoptosis:- by influencing pro- and anti-apoptotic regulators.
-Anti-inflammatory and Antioxidant Effects:-antioxidant properties help to neutralize ROS
-Anti-angiogenic Activity:may also inhibit tumor angiogenesis

Key Cellular Signaling Pathways Involved
-Estrogen Receptor Signaling: interacting with estrogen receptors (ERα and ERβ)
-PI3K/Akt/mTOR Pathway:inhibits this pro-survival pathway, leading to reduced cell growth
-MAPK/ERK Pathway: can contribute to cell cycle arrest.
-NF-κB Pathway:may downregulate NF-κB, supporting a reduction in tumor-promoting inflammation.
-Wnt/β-catenin Pathway: involved in cell proliferation, differentiation, and oncogenic transformation.

Dosages often ranging from approximately 40 mg to 100 mg per day for potential therapeutic effects. Genistein has limited bioavailability when ingested as part of the diet. Efforts to enhance its absorption include the use of specific formulations, such as those that combine genistein with other compounds or utilize novel delivery systems.

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Estrogen receptor modulation (ERβ & ERα)	ER signaling modulation (context-dependent; tissue specific)	Selective ER modulation (phytoestrogenic activity)	P, R, G	Hormone pathway modulation	Genistein binds ERs (often higher affinity for ERβ). Effects depend on tumor ER status, dose, and hormonal environment.
2	Tyrosine kinase inhibition (e.g., EGFR-related signaling)	Growth signaling ↓ (reported)	↔	P, R	Mitogenic signaling suppression	Historically described as a protein tyrosine kinase inhibitor; relevance varies by cell type and exposure level.
3	PI3K → AKT → mTOR axis	PI3K/AKT signaling ↓ (reported; model-dependent)	↔	R, G	Survival/growth modulation	Frequently reported in preclinical systems; strength of effect varies with concentration and ER context.
4	NF-κB inflammatory transcription	NF-κB activity ↓ (reported)	Inflammatory tone ↓	R, G	Anti-inflammatory transcription	Observed across inflammatory and cancer models; contributes to reduced cytokine and pro-survival gene expression.
5	Cell-cycle checkpoints (G2/M commonly reported)	Cell-cycle arrest ↑ (often G2/M)	↔	G	Cytostasis	Genistein commonly induces cell-cycle arrest, particularly at higher in-vitro concentrations.
6	Intrinsic apoptosis (mitochondrial/caspase-linked)	Apoptosis ↑ (reported; dose-dependent)	↔ (generally less activation)	G	Cell death execution	Frequently downstream of survival signaling suppression; magnitude varies by exposure level.
7	Angiogenesis signaling (VEGF)	VEGF ↓ (reported)	↔	G	Anti-angiogenic support	Reduction in angiogenic signaling is described in some tumor models; typically a later phenotype effect.
8	Epigenetic modulation (DNMT / histone effects)	DNA methylation changes (reported)	↔	G	Epigenetic reprogramming	Genistein has been reported to influence DNMT activity and gene expression patterns in preclinical studies.
9	Redox modulation (ROS)	ROS direction variable (antioxidant at low dose; pro-oxidant reported at high dose)	Antioxidant tone ↑ (common in non-tumor models)	P, R, G	Redox modulation (context-dependent)	Redox effects are dose- and model-dependent; not a reliable primary cytotoxic mechanism.
10	Bioavailability / metabolism constraint	Systemic levels largely conjugated metabolites	—	—	Translation constraint	After oral intake, genistein circulates mainly as glucuronide/sulfate conjugates; free plasma levels are typically lower than many in-vitro IC50 values.

Time-Scale Flag (TSF): P / R / G

P: 0–30 min (rapid receptor/kinase interactions)
R: 30 min–3 hr (acute transcription and signaling shifts)
G: >3 hr (gene-regulatory adaptation and phenotype outcomes)

Smo, G-protein-coupled receptor-like 7-pass transmembrane protein Smoothened: Click to Expand ⟱

Source: CGL-Driver Genes

Type: HH Oncogene

Smoothened homolog (Drosophila)
SMO, or Smoothened, is a protein that plays a crucial role in the Hedgehog signaling pathway, which is important for cell growth, differentiation, and tissue patterning during embryonic development. Inhibitors of SMO, such as vismodegib and sonidegib, have been developed as targeted therapies for cancers associated with aberrant Hedgehog signaling.
SMO (Smoothened):
- A G protein-coupled receptor (GPCR)-like protein that is a critical component of the Hedgehog (Hh) signaling pathway.
- Functions in transmitting the Hedgehog signal from the cell surface to intracellular effectors, culminating in changes in gene expression.
Aberrant Activation of the Hedgehog Pathway:
- In many cancers, mutations or dysregulations in pathway components lead to ligand-independent or ligand-dependent activation of SMO.
- This inappropriate activation can result in enhanced cell proliferation, survival, and stem cell-like
Several cancers exhibit overexpression of SMO or activating mutations leading to Hedgehog pathway activation.
Smoothened (SMO) is a critical mediator of the Hedgehog signaling pathway, with aberrant activation contributing to tumor growth, progression, and resistance to therapy. High expression or activating mutations in SMO are linked with a poor prognosis in certain cancer types, particularly in cancers that are dependent on Hedgehog pathway signaling such as basal cell carcinoma and medulloblastoma. By targeting SMO with specific inhibitors, researchers and clinicians are addressing one of the key drivers of tumorigenesis in these settings.

Scientific Papers found: Click to Expand⟱

28-

GEN,

Genistein decreases the breast cancer stem-like cell population through Hedgehog pathway

in-vivo,

BC,

MCF-7

 15-30 uM 20-50mg/kg(2wks)

HH↓, Smo↓, Gli1↓, TumCG↓, TumCP↓, Apoptosis↑, CSCs↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Cell Death ⓘ

Apoptosis↑, 1,

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1, Gli1↓, 1, HH↓, 1, Smo↓, 1, TumCG↓, 1,

Migration ⓘ

TumCP↓, 1,
Total Targets: 7

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: Smo, G-protein-coupled receptor-like 7-pass transmembrane protein Smoothened

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells